INC Research Grows Presence In Japan With Office Expansion And Relocation

Published: Jun 29, 2017

- New office will allow for global CRO to continue to support rapid growth in Asia/Pacific’s largest pharmaceutical market

RALEIGH, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the expansion and relocation of its Tokyo, Japan office in support of the Company’s long-term growth strategy both in Japan and across the Asia/Pacific region.

In the last two and a half years, INC Research’s operations in Tokyo rapidly outgrew the Company’s existing offices due to a more than four-fold increase in headcount. The new office at 27F Shinagawa Season Terrace, 1-2-70 Konan, Minato-ku, Tokyo will support expansion of INC’s presence in Japan and the Asia/Pacific region, enabling the Company to better accommodate its global drug development customers in the region.

"Our continued expansion in Tokyo demonstrates our commitment to becoming the global ‘CRO of Choice’ within this vibrant pharmaceutical market for regional and global clinical trials," said Miranda Porter, PhD, Senior Vice President, Clinical Development, Tokyo, who provides overall leadership for the Company’s Japan operations. "Our employees provide global expertise within our therapeutically aligned delivery model while providing local experience and knowledge of Japan’s regulatory, healthcare and cultural environments. Our continued expansion in the country is making a strong contribution to INC’s overall growth.”

INC Research’s lease for the new Tokyo location includes some of the most spacious office floors in Japan, measuring approximately 1,500 tsubo (16,273 square feet). The state-of-the-art Shinagawa Season Terrace, constructed in 2015, houses nearly 20 cafes and restaurants and includes vast stretches of lawn for recreational activities and events. The newly opened office is a six-minute walk to Shinagawa Station, providing easy access to a number of train lines, including Shinkansen, local JR lines, and the Keikyu line with excellent accessibility to both Haneda and Narita airports.

“We are excited to be located in such modern and convenient working space, complete with multiple amenities and adjacent space for relaxation,” continued Porter. “By maintaining our location in proximity to Shinagawa Station we are able to provide an ideal workspace for our existing employees while remaining highly competitive in attracting best-in-class talent who want to work for a global company.”

INC Research’s expansion in Japan builds on its existing 19 offices throughout the Asia/Pacific region. In addition to Tokyo and Osaka, Japan, INC Research operates from offices in China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand.

The Company has a long history of providing Phase I to IV clinical development services in the Asia/Pacific region, conducting nearly 1,200 studies across a broad range of therapeutic areas. INC Research’s unique approach to the Japan market leverages the Company’s established global expertise, innovative Trusted Process® project management methodology and strong site relationships. Local operations also feature English-speaking management and regulatory and therapeutic staff with experience delivering quality trials with full-service capabilities that balance innovation and respect for Japan-specific nuances. In addition to having a bilingual leadership team based in Japan, INC Research employs both project management and CRA staff in all key service areas, including Real World & Late Phase, Medical Devices, Study Start-up, Biometrics, Biostatistics, Project Management, Medical Monitoring, Safety and Pharmacovigilance, Medical Writing and Quality Assurance.

The core teams at both the Osaka and Tokyo offices offer decades of experience managing clinical trials within Japan across a wide array of therapeutic indications, with notable experience in Central Nervous System (CNS) and General Medicine and Oncology clinical development as well as Functional Service Provider (FSP) services.

For more information on INC Research's clinical trial services and experience in Japan, please call +81-3-6837-4700 or visit INC’s Japanese language website at http://incresearch.com/jp.

About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

CONTACT:
Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
Phone: +1 (919) 745-2745
Email: Investor.Relations@incresearch.com

Press/Media Contacts:
Lori Doer
Sr. Director, Global Corporate Communications
Phone: +1(919) 745-2890
Email: Corporate.Communications@incresearch.com

Back to news